

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is for information purposes only, and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Beijing Chunlizhengda Medical Instruments Co., Ltd.**



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

FINANCIAL INFORMATION IN RELATION TO A SHARE PROSPECTUS

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the announcements of the Company dated 3 November 2015, 22 April 2020, 5 June 2020, 22 December 2020, 22 June 2021, 28 June 2021, 7 July 2021, 19 July 2021, 6 August 2021, 12 August 2021, 20 August 2021 in relation to, among others, the A Share Offering, the circulars of the Company’s 2020 second extraordinary general meeting, 2020 second Domestic Shareholders’ class meeting and 2020 second H Shareholders’ class meeting dated 24 July 2020 and the Company’s 2021 first extraordinary general meeting, 2021 first Domestic Shareholders’ class meeting and 2021 first H Shareholders’ class meeting dated 16 July 2021, the announcement of the Company dated 10 August 2020 in relation to the poll results of the Company’s 2020 second extraordinary general meeting, 2020 second Domestic Shareholders’ class meeting and 2020 second H Shareholders’ class meeting and the announcement of the Company dated 6 August 2021 in relation to the poll results of the Company’s 2021 first extraordinary general meeting, 2021 first Domestic Shareholders’ class meeting and 2021 first H Shareholders’ class meeting. Unless the context requires otherwise, terms and expressions used in this announcement shall have the same meanings as those defined in the aforementioned announcements and circulars.

The full text of the Prospectus of Beijing Chunlizhengda Medical Instruments Co., Ltd.* for the Initial Public Offering of Shares and Listing on the STAR Market (Registration Proof) (《北京市春立正達醫療器械股份有限公司首次公開發行股票並在科創板上市招股說明書(註冊稿)》) (the “**Registration Proof A Share Prospectus**”) issued by the Company in respect of listing application for A Shares was published on the website of the Review and Approval of the Issuing and Listing Stocks on the STAR Market of the Shanghai Stock Exchange (<http://kcb.sse.com.cn/>), the website of the CSRC (<http://www.csrc.gov.cn/pub/newsite/fxjgb/kcbzczl/kcbzcsqwj/>) and the HKEXnews website of the Stock Exchange (www.hkexnews.hk) on 23 November 2021.

The major financial data of the Company for the nine months ended 30 September 2021 and the annual financial information for the year of 2021 is set out in “VIII. Major Financial Data and Operating Conditions after the Ending Date of the Audited Financial Report” under “Important Notice” and “XVII. Major Financial Data and Operating Conditions after the Ending Date of the Audited Financial Report” under “Section VIII Financial Information and Management Analysis” in the Registration Proof A Share Prospectus. The relevant financial data of the Company for the nine months ended 30 September 2021 together with its comparative figures for the corresponding period have been audited by Shenzhen Daxin Accounting Firm, the Audit Report “Daxin Yue Zi [2021] No. 3-00020” has been issued by the firm on 5 November 2021. The annual financial information for the year of 2021 is based on the preliminary estimates by the management of the Company, which has not been audited or reviewed by the Company’s auditors, and it does not indicate that the Company can ultimately achieve such operating revenue and net profit, nor does it constitute a profit forecast of the Company.

As of 30 September 2021, the Company had total assets of RMB1,739,975,300, total liabilities of RMB456,211,700 and equity attributable to the shareholders of the parent company of RMB1,283,763,600. For the nine months ended 30 September 2021, the Company achieved operating revenue of RMB718,393,300, representing a year-on-year increase of 18.31%; net profit attributable to the shareholders of the parent company amounted to RMB204,175,200, representing a year-on-year increase of 23.66%.

Based on the Company’s preliminary estimates, it is expected to achieve operating revenue from approximately RMB949,737,000 to RMB1,148,031,600 in 2021, with a year-on-year increase from 1.29% to 22.43%; net profit attributable to the shareholders of the parent company from approximately RMB269,058,100 to RMB324,195,800, with a year-on-year increase from –5.05% to 14.41%; and net profit attributable to the shareholders of the parent company after deducting non-recurring profits or losses from approximately RMB253,127,400 to RMB308,265,200, with a year-on-year increase from –8.50% to 11.43%.

As at the date of the Registration Proof A Share Prospectus, the major operating conditions of the Company are normal, and operating results are stable. No material change has occurred in the Company’s operation model, purchasing scale and purchasing price of major raw materials, production of major products, sales scale and sales price, composition of major customers and suppliers, taxation policy and others, and no other material matters that may affect the judgment of investors has occurred.

The above estimates of the Company do not constitute any guarantee of its future development, and may differ from the actual results of the Company due to various uncertainties. Such estimates do not constitute actual commitments to potential investors and shareholders of the Company. Potential investors and shareholders of the Company should be aware that inappropriate reliance on and usage of such information may expose themselves to investment risks. The English version of the relevant financial data and its reasons is an unofficial translation of its Chinese version. In case of any discrepancies, the Chinese version shall prevail.

For more details of the A Share Offering, please refer to the Registration Proof A Share Prospectus which was published on the website of the Review and Approval of the Issuing and Listing Stocks on the STAR Market of the Shanghai Stock Exchange (<http://kcb.sse.com.cn/>), the website of the CSRC (<http://www.csrc.gov.cn/pub/newsite/fxjgb/kcbzczl/kcbzcsqwj/>) and the HKEXnews website of the Stock Exchange (www.hkexnews.hk) by the Company on 23 November 2021.

As the A Share Offering is pending for approval of registration by the CSRC, Shareholders and investors should exercise caution when dealing in the H Shares of the Company. Further announcement(s) will be made in relation to any major updates and developments in respect of the A Share Offering in accordance with the Listing Rules and other applicable laws and regulations.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Chunbao
Chairman

Beijing, the PRC, 24 November 2021

As at the date of this announcement, the executive Directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.

* For identification purpose only